> top > docs > PubMed:27576368 > annotations

PubMed:27576368 JSONTXT

Annnotations TAB JSON ListView MergeView

Inflammaging

Id Subject Object Predicate Lexical cue
T1 0-152 Sentence denotes A microcosting study of immunogenicity and tumour necrosis factor alpha inhibitor drug level tests for therapeutic drug monitoring in clinical practice.
T2 153-164 Sentence denotes OBJECTIVES:
T3 165-344 Sentence denotes To identify and quantify resource required and associated costs for implementing TNF-α inhibitor (TNFi) drug level and anti-drug antibody (ADAb) tests in UK rheumatology practice.
T4 345-353 Sentence denotes METHODS:
T5 354-545 Sentence denotes A microcosting study, assuming the UK National Health Service perspective, identified the direct medical costs associated with providing TNFi drug level and ADAb testing in clinical practice.
T6 546-826 Sentence denotes Resource use and costs per patient were identified via four stages: identification of a patient pathway with resource implications; estimation of the resources required; identification of the cost per unit of resource (2015 prices); and calculation of the total costs per patient.
T7 827-938 Sentence denotes Univariate and multiway sensitivity analyses were performed using the variation in resource use and unit costs.
T8 939-947 Sentence denotes RESULTS:
T9 948-1149 Sentence denotes Total costs for TNFi drug level and concurrent ADAb testing, assessed using ELISAs on trough serum levels, were £152.52/patient (range: £147.68-159.24) if 40 patient samples were tested simultaneously.
T10 1150-1309 Sentence denotes For the base-case analysis, the pre-testing phase incurred the highest costs, which included booking an additional appointment to acquire trough blood samples.
T11 1310-1470 Sentence denotes The additional appointment was the key driver of costs per patient (67% of the total cost), and labour accounted for 10% and consumables 23% of the total costs.
T12 1471-1576 Sentence denotes Performing ELISAs once per patient (rather than in duplicate) reduced the total costs to £133.78/patient.
T13 1577-1588 Sentence denotes CONCLUSION:
T14 1589-1681 Sentence denotes This microcosting study is the first assessing the cost of TNFi drug level and ADAb testing.
T15 1682-1842 Sentence denotes The results could be used in subsequent cost-effectiveness analyses of TNFi pharmacological tests to target treatments and inform future policy recommendations.
T1 0-152 Sentence denotes A microcosting study of immunogenicity and tumour necrosis factor alpha inhibitor drug level tests for therapeutic drug monitoring in clinical practice.
T2 153-164 Sentence denotes OBJECTIVES:
T3 165-344 Sentence denotes To identify and quantify resource required and associated costs for implementing TNF-α inhibitor (TNFi) drug level and anti-drug antibody (ADAb) tests in UK rheumatology practice.
T4 345-353 Sentence denotes METHODS:
T5 354-545 Sentence denotes A microcosting study, assuming the UK National Health Service perspective, identified the direct medical costs associated with providing TNFi drug level and ADAb testing in clinical practice.
T6 546-826 Sentence denotes Resource use and costs per patient were identified via four stages: identification of a patient pathway with resource implications; estimation of the resources required; identification of the cost per unit of resource (2015 prices); and calculation of the total costs per patient.
T7 827-938 Sentence denotes Univariate and multiway sensitivity analyses were performed using the variation in resource use and unit costs.
T8 939-947 Sentence denotes RESULTS:
T9 948-1149 Sentence denotes Total costs for TNFi drug level and concurrent ADAb testing, assessed using ELISAs on trough serum levels, were £152.52/patient (range: £147.68-159.24) if 40 patient samples were tested simultaneously.
T10 1150-1309 Sentence denotes For the base-case analysis, the pre-testing phase incurred the highest costs, which included booking an additional appointment to acquire trough blood samples.
T11 1310-1470 Sentence denotes The additional appointment was the key driver of costs per patient (67% of the total cost), and labour accounted for 10% and consumables 23% of the total costs.
T12 1471-1576 Sentence denotes Performing ELISAs once per patient (rather than in duplicate) reduced the total costs to £133.78/patient.
T13 1577-1588 Sentence denotes CONCLUSION:
T14 1589-1681 Sentence denotes This microcosting study is the first assessing the cost of TNFi drug level and ADAb testing.
T15 1682-1842 Sentence denotes The results could be used in subsequent cost-effectiveness analyses of TNFi pharmacological tests to target treatments and inform future policy recommendations.

Wangshuguang

Id Subject Object Predicate Lexical cue
T1 269-273 B-Variation denotes drug
T2 274-279 I-Variation denotes level
T3 496-500 B-Variation denotes drug
T4 501-506 I-Variation denotes level
T5 516-523 B-Regulation denotes testing
T6 524-526 I-Regulation denotes in
T7 606-612 B-Variation denotes stages
T8 738-742 B-Variation denotes cost
T9 743-746 I-Variation denotes per
T10 747-751 I-Variation denotes unit
T11 969-973 B-Variation denotes drug
T12 974-979 I-Variation denotes level
T13 1613-1615 B-Negtive_Regulation denotes is
T14 1640-1644 B-Negative_Function denotes cost
T15 1653-1657 B-Variation denotes drug
T16 1658-1663 I-Variation denotes level

123123123

Id Subject Object Predicate Lexical cue
T1 269-273 B-Variation denotes drug
T2 274-279 I-Variation denotes level
T3 496-500 B-Variation denotes drug
T4 501-506 I-Variation denotes level
T5 516-523 B-Regulation denotes testing
T6 524-526 I-Regulation denotes in
T7 606-612 B-Variation denotes stages
T8 738-742 B-Variation denotes cost
T9 743-746 I-Variation denotes per
T10 747-751 I-Variation denotes unit
T11 969-973 B-Variation denotes drug
T12 974-979 I-Variation denotes level
T13 1613-1615 B-Negtive_Regulation denotes is
T14 1640-1644 B-Negative_Function denotes cost
T15 1653-1657 B-Variation denotes drug
T16 1658-1663 I-Variation denotes level